Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759642 · ClinicalTrials.gov registry record · Phase 2
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00759642 is a Phase 2 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 33 participants.
The verdict
NCT00759642, a Phase 2 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer. Endocrine therapy is treatment that tries to remove, or block certain hormones from binding to the cancer cells and thus slow or stop the growth of cancer. Although most patients with your type of breast cancer respond initially to endocrine therapies, it can lose its effectiveness. New therapies for this type of cancer are needed.
Interventions
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-03 |
| Est. Completion | 2018-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759642
The ClinicalTrials.gov registry entry for NCT00759642 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lapatinib is the first listed.
NCT00759642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00759642 about?
NCT00759642 is a clinical study titled "Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy". Hormone receptor positive breast cancer is the most common type of breast cancer, comprising 70-80% of all breast cancers. Endocrine therapy is the main type of initial treatment for patients with your type of breast cancer. Endocrine therapy is treatment that tries to remove, or block certain hormo...
What is the current status of trial NCT00759642?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2009-03. Estimated completion is 2018-08-20.
What interventions are being tested in trial NCT00759642?
The interventions under investigation include: lapatinib (DRUG).
Who is sponsoring clinical trial NCT00759642?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.